CJC-DAC
CJC-1295 with Drug Affinity Complex that extends half-life dramatically, providing sustained GH elevation over days rather than hours.
Regulatory status (as of Sept 2026)
Not FDA-approved. Not among the peptides named in the 2026 PCAC actions.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote1 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
CJC-1295 (with DAC) is a compound with only early, small human studies so far. CJC-1295 with Drug Affinity Complex that extends half-life dramatically, providing sustained GH elevation over days rather than hours.
| Half-life | 6-8 days |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Phase 1 / early human |
| Dosing | Published research: Healthy adults aged 21-61: single subcutaneous ascending doses, then 2-3 weekly or biweekly subcutaneous doses detailsHealthy adults aged 21-61: single s.c. ascending doses, then 2-3 weekly or biweekly s.c. doses. Best tolerated at 30 or 60 µg/kg (Teichman 2006). That is about 2-4 mg per dose for a 70 kg adult, given once, weekly or every 2 weeks, over 28-49 days.Community-reportedCommunity-reported: 1–2 mg per week, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a long-acting version of the hormone that tells the pituitary to release growth hormone, so its effect lasts for days. GHRH analogue with a drug affinity complex (DAC) modification designed to bind albumin and prolong its action. In two placebo-controlled trials in healthy adults, single and repeated subcutaneous doses produced prolonged increases in GH and IGF-I (Teichman 2006).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported doses of 1–2 mg per week (subcutaneous injection). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| CJC-1295 (with DAC) | 6-8 days | Subcutaneous injection | Phase 1 / early human |
| CJC-1295 (no DAC) | No published PK data found | Subcutaneous injection | Preclinical (animal) |
| GHRP-2 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
| GHRP-6 | No published PK data found | Subcutaneous injection | Phase 1 / early human |
| Hexarelin | No published PK data found | Subcutaneous injection | Phase 1 / early human |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Growth Hormone category. View All Growth Hormone Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.